Immunotherapy for pancreatic cancer using iPS cell-derived dendritic cell and autophagy-inducing oncolytic virus

2015 Fiscal Year Final Research Report

• Project/Area Number: 25670560
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: General surgery
• Research Institution: Wakayama Medical University
• Principal Investigator: Yamaue Hiroki 和歌山県立医科大学, 医学部, 教授 (20191190)
• Co-Investigator(Kenkyū-buntansha): Nakamori Mikihito 和歌山県立医科大学, 医学部, 准教授 (10322372) ; Kawai Manabu 和歌山県立医科大学, 医学部, 講師 (40398459) ; Ojima Toshiyasu 和歌山県立医科大学, 医学部, 講師 (60448785) ; Hirono Seiko 和歌山県立医科大学, 医学部, 講師 (60468288)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: 膵癌 / 免疫療法 / 樹状細胞 / 癌治療用ウイルス

Outline of Final Research Achievements

We developed recombinant oncolytic herpes simplex viruses that possess certain antitumor functions and are useful for gastric cancer therapy. A third-generation oncolytic herpes simplex virus type 1(T-01) was used as the backbone to insert foreign sequences. Oncolytic herpes simplex viruses expressing suppressor of cytokine signaling 3 (T-SOCS-3) were constructed, evaluated, and proved to be therapeutic potential. T-SOCS-3 may be a new agent against pancreatic cancer in the near future, and a progress has been made in the basic development of next generation onoclytic virotherapy.In addition, we confirmed that iPS cell derived dendritic cell was able to enhance antitumor immunity at the oncolyitic condition of tumor microenvironment.

Free Research Field

膵臓外科学